BiotechTube
Yurogen Biosystems

Yurogen Biosystems

Worcester, United States· Est.
yurogen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

Yurogen Biosystems is a privately held, revenue-generating contract research organization (CRO) specializing in custom monoclonal antibody development for research, diagnostic, and therapeutic applications. Its core technology is the SMab™ single-B-cell platform, which it uses to generate antibodies from rabbits, camelids, and humans with a focus on speed and intellectual property security. The company's strategic merger with ABclonal and its East Asian expansion position it as a global service provider, primarily catering to biotech and pharmaceutical clients without taking therapeutic programs to market itself. Its business model is built on providing high-throughput, fee-for-service antibody development and bioanalytical reagents.

Antibodies

Technology Platform

SMab™, a single-B-cell-based monoclonal antibody development platform used for generating rabbit, camelid (VHH), and human antibodies. It includes AI-assisted design for rabbit antibodies and supports scFv engineering for in vivo CAR-T applications.

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The merger with ABclonal expands Yurogen's business from a pure-service CRO into the large-scale research reagent market, creating cross-selling opportunities and revenue diversification.
Geographic expansion into China via its Wuhan branch positions the company to capture significant growth in the Asia-Pacific biopharma R&D sector.

Risk Factors

Revenue is highly dependent on client R&D budgets, making it vulnerable to biotech funding cycles.
Intense competition in the antibody CRO and reagent space requires continuous technological innovation to maintain differentiation.
Operating in both the US and China introduces geopolitical, trade, and intellectual property protection complexities.

Competitive Landscape

Yurogen competes in a crowded field of antibody service providers, including large CROs (e.g., Charles River, Labcorp) and specialized antibody companies (e.g., GenScript, Absolute Antibody). Its differentiation lies in its single-B-cell platform speed, species expertise (rabbit, camelid), and its post-merger integrated model as both a service provider and reagent supplier via ABclonal.

More companies in Biologics / Biosimilars →More companies in United States →